| Literature DB >> 26487909 |
Kushalava Reddy Yempalla1, Gurunadham Munagala1, Samsher Singh1, Asmita Magotra1, Sunil Kumar1, Vikrant Singh Rajput1, Sonali S Bharate1, Manoj Tikoo1, G D Singh1, Inshad Ali Khan1, Ram A Vishwakarma1, Parvinder Pal Singh1.
Abstract
Whole-cell screening of 20,000 drug-like small molecules led to the identification of nitrofuranyl methylpiperazines as potent anti-TB agents. In the present study, validation followed by medicinal chemistry has been used to explore the structure-activity relationship. Ten compounds demonstrated potent MIC in the range of 0.17-0.0072 μM against H37Rv Mycobacterium tuberculosis (MTB) and were further investigated against nonreplicating and resistant (Rif(R) and MDR) strains of MTB. These compounds were also tested for cytotoxicity. Among the 10 tested compounds, five showed submicromolar to nanomolar potency against nonreplicating and resistant (Rif(R) and MDR) strains of MTB along with a good safety index. Based on their overall in vitro profiles, the solubility and pharmacokinetic properties of five potent compounds were studied, and two analogues, 14f and 16g, were found to have comparatively better solubility than others tested and acceptable pharmacokinetic properties. This study presents the rediscovery of a nitrofuranyl class of compounds with improved aqueous solubility and acceptable oral PK properties, opening a new direction for further development.Entities:
Keywords: 6-nitro-2,3-dihydroimidazooxazole; MTB H37Rv; Mycobacterium tuberculosis; multidrug resistant-TB; structure−activity relationship
Year: 2015 PMID: 26487909 PMCID: PMC4601053 DOI: 10.1021/acsmedchemlett.5b00141
Source DB: PubMed Journal: ACS Med Chem Lett ISSN: 1948-5875 Impact factor: 4.345